Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer

被引:7
|
作者
Rehman, Khurram [1 ]
Iqbal, Zoya [2 ,3 ]
Zhiqin, Deng [2 ,3 ]
Ayub, Hina [4 ]
Saba, Naseem [4 ]
Khan, Muzammil Ahamd [5 ]
Yujie, Liang [6 ]
Duan, Li [2 ,3 ]
机构
[1] Gomal Univ, Fac Pharm, D I Khan, Pakistan
[2] Shenzhen Univ, Affiliated Hosp 1, Peoples Hosp 2, Dept Orthoped, Shenzhen 518035, Guangdong, Peoples R China
[3] Shenzhen Second Peoples Hosp, Guangdong Prov Res Ctr Artificial Intelligence & D, Shenzhen 518035, Guangdong, Peoples R China
[4] Gomal Med Coll, Dept Gyne, D I Khan, Pakistan
[5] Inst Biochem & Biotechnol, D I Khan, Pakistan
[6] Shenzhen Kangning Hosp, Shenzhen Mental Hlth Ctr, Dept Child & Adolescent Psychiat, Shenzhen 518035, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
SNPs; Androgen metabolism; Pharmacotherapy; Biomarkers; Prostate cancer; Genetic polymorphism; ANDROGEN-DEPRIVATION THERAPY; SINGLE NUCLEOTIDE POLYMORPHISMS; BINDING-SITES; TRANSPORTERS IMPLICATIONS; CASTRATION RESISTANCE; CAUCASIAN PATIENTS; CLINICAL-OUTCOMES; PHASE-II; PROGRESSION; ASSOCIATION;
D O I
10.1186/s12935-023-03084-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in incidence rates across the globe. It is the second most reported cause of cancer death. Its etiology may have been linked to genetic polymorphisms, which are not only dominating cause of malignancy casualties but also exerts significant effects on pharmacotherapy outcomes. Although many therapeutic options are available, but suitable candidates identified by useful biomarkers can exhibit maximum therapeutic efficacy. The single-nucleotide polymorphisms (SNPs) reported in androgen receptor signaling genes influence the effectiveness of androgen receptor pathway inhibitors and androgen deprivation therapy. Furthermore, SNPs located in genes involved in transport, drug metabolism, and efflux pumps also influence the efficacy of pharmacotherapy. Hence, SNPs biomarkers provide the basis for individualized pharmacotherapy. The pharmacotherapeutic options for PCa include hormonal therapy, chemotherapy (Docetaxel, Mitoxantrone, Cabazitaxel, and Estramustine, etc.), and radiotherapy. Here, we overview the impact of SNPs reported in various genes on the pharmacotherapy for PCa and evaluate current genetic biomarkers with an emphasis on early diagnosis and individualized treatment strategy in PCa.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Polymorphisms of GSTP1 and related genes and prostate cancer risk
    Beer T.M.
    Evans A.J.
    Hough K.M.
    Lowe B.A.
    McWilliams J.E.
    Henner W.D.
    Prostate Cancer and Prostatic Diseases, 2002, 5 (1) : 22 - 27
  • [22] Single nucleotide polymorphisms in androgen-related genes and prostate cancer
    Gos, M.
    Sadowska, M.
    Wiechno, P.
    Demkow, T.
    Janik, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Tang, Li
    Platek, Mary
    Yao, Song
    Till, Cathee
    Goodman, Phyllis
    Tangen, Catherine M.
    Wu, Yue
    Platz, Elizabeth A.
    Neuhouse, Marian L.
    Stanczyk, Frank Z.
    Reichardt, Juergen K.
    Santella, Regina M.
    Hsing, Ann
    Figg, William D.
    Lippman, Scott M.
    Thompson, Ian M.
    Ambrosone, Christine B.
    CANCER RESEARCH, 2017, 77
  • [24] Investigation of Genetic Polymorphisms Related to the Outcome of Radiotherapy for Prostate Cancer Patients
    Cintra, Hellen Silva
    Dourado Pinezi, Juliana Castro
    Pinheiro Machado, Graziella Dias
    de Carvalho, Gustavo Moura
    Silva Carvalho, Ana Terra
    Dias dos Santos, Thalles Eduardo
    Marciano, Ricardo Duarte
    Ascenco Soares, Renata de Bastos
    DISEASE MARKERS, 2013, 2013 : 701 - 710
  • [25] Genetic polymorphisms of cancer related-genes for gastric and esophageal carcinogenesis
    Kato, S
    Onda, M
    Matsukura, N
    Tokunaga, A
    Matsuda, N
    Yoshiyuki, T
    Miyashita, M
    Sasajima, K
    Yamashita, K
    Shields, PG
    RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, 1996, : 317 - 320
  • [26] Genetic polymorphisms in obesity-related genes and endometrial cancer risk
    Chen, Xiaoli
    Xiang, Yong-Bing
    Long, Ji-Rong
    Cai, Hui
    Cai, Qiuyin
    Cheng, Jiarong
    Wen, Wanqing
    Gao, Yu-Tang
    Zheng, Wei
    Shu, Xiao-Ou
    CANCER, 2012, 118 (13) : 3356 - 3364
  • [27] Genetic polymorphisms and prostate cancer risk
    Gsur, A
    Feik, E
    Madersbacher, S
    WORLD JOURNAL OF UROLOGY, 2004, 21 (06) : 414 - 423
  • [28] Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes
    Ntais, C
    Polycarpou, A
    Tsatsoulis, A
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 149 (06) : 469 - 477
  • [29] Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer
    Zhang, X. J.
    Liu, P.
    Zhu, F.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (02) : 4419 - 4424
  • [30] Genetic polymorphisms and prostate cancer risk
    Andrea Gsur
    Elisabeth Feik
    Stephan Madersbacher
    World Journal of Urology, 2004, 21 : 414 - 423